Stocks Health care ZYBT
NASDAQ · Health careZhengye Biotechnology Holding Ltd (ZYBT)
Zhengye Biotechnology Holding Ltd reported revenue of $16.6M in fiscal 2025, down 34.8% from a year earlier. It posted a net loss of $10M. Operating cash flow minus capital spending left $1.8M of free cash flow in fiscal 2025. At December 31, 2025 it held $7.2M in cash against $1.4M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 28, 2026.
Key facts about Zhengye Biotechnology Holding Ltd
- Net worth
- Zhengye Biotechnology Holding Ltd has a market value (market cap) of $70.6M at the latest share price, and shareholders' equity of $35.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $16.6M (-34.8% year on year), with a net loss of $10M.
- Cash flow
- In fiscal 2025 operations brought in $1.9M of cash; after $144K of capital spending, free cash flow was $1.8M.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 28, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Zhengye Biotechnology Holding Ltd does
Zhengye Biotechnology Holding Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZYBT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $16.6M | -$10M | n/a | $1.8M |
| 2024 | $25.5M | $1.6M | $0.03 | $3.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ZYBT ranks in Health care
Dividends
It paid out $2.2M in cash dividends, 142% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2024 | n/a | $2.2M | 142% |
Latest SEC filings
What Zhengye Biotechnology Holding Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026
- July 21, 2026
- June 4, 2026
- April 28, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue fell 35% to $16.6M versus the prior year; net loss of $10M versus net income of $1.6M.
- March 25, 2026
- March 2, 2026
- February 23, 2026
- December 12, 2025
- July 3, 2025Annual report (foreign issuer) 20-F · period to December 31, 2024Revenue was $25.5M; diluted EPS was $0.03.
- May 23, 2025
Insider trades
What the people running Zhengye Biotechnology Holding Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ZYBT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Securingium Holding Limited13G, passive with 8 related filers | 90.66% | February 21, 2025 |
Largest institutional holders
Insiders
Questions about ZYBT
What does Zhengye Biotechnology Holding Ltd do?
Zhengye Biotechnology Holding Ltd is a company in the Health care sector, listed on NASDAQ as ZYBT. Its shares trade on NASDAQ under the ticker ZYBT.
What is Zhengye Biotechnology Holding Ltd's net worth?
Zhengye Biotechnology Holding Ltd has a market value (market cap) of $70.6M at the latest share price, and shareholders' equity of $35.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zhengye Biotechnology Holding Ltd profitable?
No. In fiscal 2025 it reported a net loss of $10M on revenue of $16.6M.
How much revenue does Zhengye Biotechnology Holding Ltd make?
In fiscal 2025 Zhengye Biotechnology Holding Ltd reported revenue of $16.6M. That is 34.8% less than a year earlier.
When did Zhengye Biotechnology Holding Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 28, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 6, 2026.
Similar companies
Compare ZYBT with
Follow ZYBT
Get an email when Zhengye Biotechnology Holding Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zhengye Biotechnology Holding Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.